Clinical Trial Search

Primary: Change From Baseline in Trough FEV1 at Day 15 — 0.1904; 0.2260; -0.0222 Liters — p=<0.0001

Primary: Sustained Virologic Response (SVR) — 10; 10 Participants

Primary: Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response — 204; 198 Participants

Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 18.38; 14.53 Lesions — p=<0.0001

Primary: Capnography Measured CO2 Waveform Data as a Function of CO2 Cannula Sampling Filterline (CCSF) Stratified by Activity — 30.6; 0.0; 26.6; 0.2 mmHg

Primary: Acceptability: System Usability Scale — 75.76 score on a scale

Primary: Number of Participants With Successful Safe Oral Feeding — 51; 31 Participants — p=0.008

Primary: Percentage of Participants Experiencing Treatment Emergent Adverse Events — 17.6; 25.0; 26.7; 8.3 percentage of participants

Primary: Change in Score on Clinician Administered PTSD Scale for the DSM-5 (CAPS-5) — 33.10; 16.13 score on a scale — p=0.01

Primary: Total Sedentary Time Per Day — 618; 660; 564; 650 minute/day

Primary: Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC) — 0.94; 0.91 probability

Primary: Mean Overall Maximum Temperature of the Cornea and Surrounding Eye Tissue Immediately Post-treatment — 37.7; 38.5; 38.2 degrees Celsius

Primary: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) — 0.94; 1.86 Events/year — p=<0.0001

Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 20 — -0.13; -0.02; -1.03; 0.57 Percentage

Primary: Percentage of Participants Randomized — 100; 100 percentage of participants randomized